Ajanta Pharma Limited (BOM:532331)

India flag India · Delayed Price · Currency is INR
2,683.95
+5.80 (0.22%)
At close: Apr 22, 2025
25.66%
Market Cap 335.81B
Revenue (ttm) 45.32B
Net Income (ttm) 8.98B
Shares Out n/a
EPS (ttm) 71.57
PE Ratio 37.40
Forward PE n/a
Dividend 54.00 (2.01%)
Ex-Dividend Date Nov 6, 2024
Volume 1,465
Average Volume 2,897
Open 2,670.55
Previous Close 2,678.15
Day's Range 2,659.30 - 2,698.60
52-Week Range 2,022.05 - 3,485.75
Beta n/a
RSI 62.81
Earnings Date May 2, 2025

About Ajanta Pharma

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited ... [Read more]

Industry Pharmaceutical Preparations
Founded 1973
Employees 8,073
Stock Exchange Bombay Stock Exchange
Ticker Symbol 532331
Full Company Profile

Financial Performance

In 2023, Ajanta Pharma's revenue was 42.09 billion, an increase of 12.45% compared to the previous year's 37.43 billion. Earnings were 8.16 billion, an increase of 38.81%.

Financial Statements

News

Stocks to buy today on brokerages’ call: IndiGo, Ajanta Pharma, TBO, HDFC Bank, Vodafone Idea among top picks – Check investment target

Several brokerage firms have issued fresh calls on select Indian stocks, highlighting investment opportunities and risks across sectors. While these are views expressed by the respective brokerage hou...

9 days ago - Business Upturn

Jefferies initiates Buy on Ajanta Pharma, sees 11% upside due to strong presence in branded generics markets

Jefferies has initiated coverage on Ajanta Pharma with a ‘Buy’ call, projecting an upside of 11% from the current market price of ₹2,574.00 (as of April 11, 2025). The brokerage has set a target price...

9 days ago - Business Upturn

Stocks to watch today: Interglobe Aviation, Ajanta Pharma, HDFC Bank, Vodafone Idea, Hindalco, TBO, L&T in focus on brokerage reports

A host of stocks are likely to remain in the spotlight today as several brokerages have issued fresh commentary and call actions, including upgrades, initiations, and revised target prices. Among the ...

9 days ago - Business Upturn

Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, PAT Up 11% to Rs 233 crore

According to IQVIA MAT December 2024 data, Ajanta Pharma’s India growth was 11%, outpacing the Indian Pharmaceutical Market (IPM) growth of 8%.

3 months ago - Business Upturn

Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%

The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...

5 months ago - Business Upturn

Ajanta Pharma declares first interim dividend of ₹28 per share for FY25

Ajanta Pharma Ltd. has announced its first interim dividend for the financial year 2024-25. Each share with a face value of ₹2 will receive a dividend of ₹28, totaling an outlay of ₹350 crore. The com...

6 months ago - Business Upturn

Ajanta Pharma Q2 FY25 Results: Revenue rises 15% to ₹1,187 crore, net profit grows 11% to ₹216 crore

Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, has released its Q2 FY25 results, showcasing a strong performance for the quarter and half-year ending on 30th September 2024. Key H...

6 months ago - Business Upturn